| Samantha Carella, CRNA | |
|
2500 Merced St, San Leandro, CA 94577-4201 | |
| (510) 454-1000 | |
| Not Available |
| Full Name | Samantha Carella |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 2500 Merced St, San Leandro, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568913044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 95000255 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
The November 21 cover story of Forbes magazine profiles Bill Gates, Microsoft founder and co-chair of the Bill & Melinda Gates Foundation, which has focused its global health efforts on vaccine development and distribution, according to the article.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
Each year millions of children and adults in the world's poorest countries die from lack of access to medicine and health care. A new report from Rice University's Jones Graduate School of Business and the George W. Bush Institute offers a solution for improving distribution methods for health care information, products and services.
› Verified 3 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
The November 21 cover story of Forbes magazine profiles Bill Gates, Microsoft founder and co-chair of the Bill & Melinda Gates Foundation, which has focused its global health efforts on vaccine development and distribution, according to the article.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
Each year millions of children and adults in the world's poorest countries die from lack of access to medicine and health care. A new report from Rice University's Jones Graduate School of Business and the George W. Bush Institute offers a solution for improving distribution methods for health care information, products and services.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Carella, CRNA 2500 Merced St, San Leandro, CA 94577-4201 Ph: (510) 454-1000 | Samantha Carella, CRNA 2500 Merced St, San Leandro, CA 94577-4201 Ph: (510) 454-1000 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
The November 21 cover story of Forbes magazine profiles Bill Gates, Microsoft founder and co-chair of the Bill & Melinda Gates Foundation, which has focused its global health efforts on vaccine development and distribution, according to the article.
The Center for Strategic & International Studies (CSIS) on Monday "hosted the public launch of the new USAID Global Health Strategy to support implementation of the Global Health Initiative," according to its website.
A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
Each year millions of children and adults in the world's poorest countries die from lack of access to medicine and health care. A new report from Rice University's Jones Graduate School of Business and the George W. Bush Institute offers a solution for improving distribution methods for health care information, products and services.
› Verified 3 days ago
Jennifer Lim, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Joseph J Janakes, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2500 Merced St, Department Of Anesthesia, San Leandro, CA 94577 Phone: 510-454-2070 | |
Steven Bazan, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-2070 | |
Franchesca Maria Cascone, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-2070 | |
Belinda Will, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-2070 | |
Mrs. Jaclyn G Cho, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Mrs. Katherine T La, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-2070 |